Protective effect of the extract of Yi-Qi-Fu-Mai preparation on hypoxia-induced heart injury in mice.
10.1016/S1875-5364(16)30035-8
- Author:
Ya-Qian FENG
1
,
2
;
Ai-Chun JU
3
;
Chun-Hua LIU
4
;
Ting WANG
4
;
Bo-Yang YU
1
,
5
;
Jin QI
1
,
6
Author Information
1. State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, Jiangsu 210009, China
2. Jiangsu Key Laboratory of TCM Evaluation and Translational Research, China Pharmaceutical University, Nanjing, Jiangsu 210038, China.
3. Department of Technology Development, TianJin Tasly Pride Pharmaceutical Co., Ltd., Tianjin 300410, China.
4. Jiangsu Key Laboratory of TCM Evaluation and Translational Research, China Pharmaceutical University, Nanjing, Jiangsu 210038, China.
5. Jiangsu Key Laboratory of TCM Evaluation and Translational Research, China Pharmaceutical University, Nanjing, Jiangsu 210038, China. Electronic address: boyangyu59@163.com.
6. Jiangsu Key Laboratory of TCM Evaluation and Translational Research, China Pharmaceutical University, Nanjing, Jiangsu 210038, China. Electronic address: qijin2006@163.com.
- Publication Type:Journal Article
- Keywords:
Cardiac damage;
Chronic intermittent hypoxia;
Extract of YQFM preparation
- MeSH:
Animals;
Creatine Kinase;
metabolism;
Disease Models, Animal;
Drugs, Chinese Herbal;
administration & dosage;
Heart;
drug effects;
Heart Injuries;
enzymology;
etiology;
metabolism;
prevention & control;
Humans;
Hypoxia;
complications;
L-Lactate Dehydrogenase;
metabolism;
Male;
Malondialdehyde;
metabolism;
Mice;
Superoxide Dismutase;
metabolism
- From:
Chinese Journal of Natural Medicines (English Ed.)
2016;14(6):401-406
- CountryChina
- Language:English
-
Abstract:
Yi-Qi-Fu-Mai (YQFM) is extensively used clinically to treat cardiovascular diseases in China. To explore the anti-hypoxia effect of the extract of YQFM preparation (EYQFM), the EYQFM (1.4, 2.8, and 5.5 g·kg(-1)·d(-1)) was assessed for its heart-protective effect in a chronic intermittent hypoxia (CIH) animal model (oxygen pressure 7%-8%, 20 min per day) for 28 days of treatment. Betaloc (0.151 6 g·kg(-1)·d(-1)) was used as a positive control. The histopathological analyses of heart in CIH mice were conducted. Several cardiac state parameters, such as left ventricular ejection fractions (EF), stroke volume (SV), expression of creatine kinase (CK), lactate dehydrogenase (LDH), superoxide dismutase (SOD), and malondialdehyde (MDA) were measured. The results showed that treatment with EYQFM markedly reversed swelling of the endothelial cells and vacuolization in the heart when compared with the model group. Further study demonstrated that EYQFM significantly improved ventricular myocardial contractility by increasing EF and SV. In addition, EYQFM inhibited the activity of CK, LDH, decreased the level of MDA and improved SOD activity. The results demonstrated that EYQFM significantly improved the tolerability of myocardium to hypoxia and ameliorated the cardiac damage in the CIH model.
